The patient has an elevated thyroid‑stimulating hormone (TSH) and is not on levothyroxine; what management is recommended?

Management of TSH 5.76 in Treatment-Naïve Patient

For a patient with TSH 5.76 mIU/L not on levothyroxine, do not routinely start treatment—instead, repeat thyroid function tests in 2-3 months to confirm persistent elevation, as 62% of elevated TSH levels spontaneously normalize. 1, 2

Initial Diagnostic Approach

Confirm the Diagnosis

• Repeat TSH and free T4 in 2-3 months before making treatment decisions 1, 3
• Add thyroid peroxidase antibody (anti-TPO) testing during repeat assessment 3
• This TSH level (5.76 mIU/L) falls in the "mild subclinical hypothyroidism" range (TSH 4.5-10 mIU/L per JAMA guidelines, or 6.8-10 mIU/L per Korean guidelines) 1, 3

Critical Context to Assess

Pregnancy status is the game-changer here:

• If pregnant or planning pregnancy: START levothyroxine immediately to restore TSH to reference range, regardless of TSH level, due to risks of fetal wastage and neuropsychological complications in offspring 1
• Check for: family/personal history of thyroid disease, type 1 diabetes, autoimmune disorders, or symptoms of hypothyroidism 1

Patient age matters significantly:

• If age ≥70 years: generally do NOT treat regardless of TSH level, as treatment may be harmful in elderly patients 4, 2
• If age <70 years: proceed with algorithm below 3

Treatment Decision Algorithm (Non-Pregnant Adults <70 Years)

For TSH 5.76 mIU/L (Confirmed on Repeat Testing):

Do NOT routinely start levothyroxine because: 1, 5

• Randomized controlled trials show no clinically relevant benefits for quality of life, thyroid-related symptoms, depressive symptoms, fatigue, or body mass index (moderate to high quality evidence) 5
• Treatment does not improve symptoms or cognitive function when TSH <10 mIU/L 2
• The likelihood of symptomatic improvement is small and must be balanced against lifelong treatment burden 1

Consider Treatment Trial ONLY If:

1. Severe hypothyroid symptoms are present AND patient strongly desires trial 1

   • Trial levothyroxine for several months
   • Continue ONLY if clear symptomatic benefit occurs
   • Distinguish true therapeutic effect from placebo is difficult 1

2. Concurrent cardiovascular disease (coronary artery disease or heart failure) 3

3. Concurrent dyslipidemia that may benefit from treatment 3

4. Anti-TPO antibodies positive (predicts 4.3% annual progression to overt hypothyroidism vs 2.6% if negative) 1

Monitoring Strategy if NOT Treating:

• Repeat TSH every 6-12 months to monitor for progression 1
• Understand natural history: small but definite risk of progression to overt hypothyroidism (higher with positive antibodies) 1
• Treat if TSH rises above 10 mIU/L or symptoms develop 1

Special Populations Requiring Different Approach

If TSH Were >10 mIU/L (Not Your Case, But Important):

• Levothyroxine therapy is reasonable at this threshold 1
• 5% annual progression rate to overt hypothyroidism 1
• May reduce cardiovascular events in patients <65 years 2

Elderly Patients (≥70 years):

• Do NOT treat even with TSH 5.76 mIU/L 4, 3, 2
• Age-related TSH reference ranges: 97.5th percentile is 7.5 mIU/L for age >80 2
• Treatment may be harmful in this population 2

Common Pitfalls to Avoid

1. Treating based on single TSH measurement without confirmation 3, 2
2. Overtreating mild subclinical hypothyroidism contributes to patient dissatisfaction when symptoms don't improve 2
3. Not checking pregnancy status before deciding—this completely changes management 1
4. Ignoring age-specific TSH reference ranges—what's "elevated" at age 40 may be normal at age 80 2
5. Starting treatment without clear endpoints—if you trial therapy, define what "success" looks like beforehand 1

Bottom Line for Your Patient

With TSH 5.76 mIU/L, repeat testing in 2-3 months with anti-TPO antibodies. If confirmed and patient is not pregnant and <70 years old, monitor without treatment unless specific indications exist (severe symptoms, cardiovascular disease, or dyslipidemia). The evidence strongly supports watchful waiting over routine treatment at this TSH level. 1, 5